Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.
In a multicenter, phase II trial, CI-958, a benzothiopyranoindazole DNA intercalator, was administered to 18 patients who had not received prior chemotherapy for metastatic colorectal cancer. The drug was given by intravenous infusion at a dose of 700 mg/m2 every 21 days. There were no objective responses. Grades III and IV toxic effects were limited to granulocytopenia in 42% of courses and anemia in 5% of courses. There was one case of grade III increase in transaminases. Our results show that at this dose and schedule, CI-958 lacks activity against colorectal cancer.
Hoff
P M
PM
Division of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Ellerton
J A
JA
Dakhil
S R
SR
Winn
R J
RJ
Abbruzzese
J L
JL
Pazdur
R
R
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D007191:Indazoles; C054558:ledoxantrone